Stay updated on Atezo/Chemo +/- Tiragolumab in Untreated ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Atezo/Chemo +/- Tiragolumab in Untreated ES-SCLC Clinical Trial page.

Latest updates to the Atezo/Chemo +/- Tiragolumab in Untreated ES-SCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe footer now displays ClinicalTrials.gov release v3.8.0 instead of v3.7.2. Study record details are unchanged.SummaryDifference0.1%

- Check21 days agoChange DetectedA sitewide NIH banner announces updates and FAQs about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference0.4%

- Check28 days agoChange DetectedThe footer's site revision indicator changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check35 days agoChange DetectedThe ClinicalTrials.gov site revision indicator changed from v3.7.0 to v3.7.1; the study record content remains unchanged.SummaryDifference0.1%

- Check56 days agoChange DetectedThe study history now includes additions of Adverse Events, Outcome Measures (Results), Baseline Characteristics, and Participant Flow as part of the Document Section updates, tied to revision v3.7.0 (38) around 2026-09-15 to 2026-09-18.SummaryDifference0.9%

- Check77 days agoChange DetectedNew revision label v3.6.6 appears in the record history, and the previous revision v3.6.5 is removed. This indicates the study record history has been updated to reflect the latest version of the record.SummaryDifference0.1%

Stay in the know with updates to Atezo/Chemo +/- Tiragolumab in Untreated ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezo/Chemo +/- Tiragolumab in Untreated ES-SCLC Clinical Trial page.